Long noncoding RNA polymorphisms in gynecological cancers

Gynecological malignancies are one of the main causes of cancer-induced mortality. Despite remarkable recent therapeutic advances, current therapeutic options are not sufficient. Regarding the effect of long noncoding RNAs (lncRNAs) on cell differentiation, proliferation and apoptosis, variations in their expression cause different anomalies, such as tumorigenesis. SNPs influence lncRNA function and expression. LncRNA polymorphisms can predict cancer risk and are effective for early diagnosis and customized therapy. In this literature review, we comprehensively investigate the effect of lncRNA polymorphisms on gynecological cancers. LncRNA-related variants are proposed to evaluate cancer incidence, early detection and management of personalized therapy. Nonetheless, more studies are required to validate the consistency of current findings in numerous samples and across various ethnic groups.

LncRNA polymorphisms and lung cancer risk

Lung cancer (LC) imposes a significant burden, and is associated with high mortality and morbidity among malignant tumors. Aberrant expression of particular lncRNAs is closely linked to LC. LncRNA polymorphisms cause abnormal expression levels and/or structural dysfunction. They can affect the progression of cancer, survival, response to chemotherapy and recurrence rates in cancer patients. The present article provides a comprehensive overview of the effect of lncRNA genetic polymorphisms on LC. It is proposed that lncRNA-related variants can be used to predict cancer risk and therapeutic outcomes. More large-scale trials on diverse ethnic groups are required to validate the results, thus personalizing LC therapy based on lncRNA genotypes.

Comparison between SPATA18 and P53 Gene Expressions in The Sperm Cells Obtained from Normospermic and Asthenospermic Samples: A Case-Control Study

Background

Improving sperm motility results in increasing the success of a treatment cycle. Recently, sperm RNA has been used for diagnostic purposes such as whole seminal fluid, sperm analysis, and sperm quality test in patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). SPATA18-P53 pathway is considered an essential pathway related to sperm mitochondria, which controls mitochondrial quality by eliminating its oxidative proteins. Oxidative stress may decrease sperm motility and affect sperm quality negatively due to an increase in P53 expression. SPATA18 protein is found in satellite fibers related to outer dense fibers in the middle piece of sperm. The downregulation of SPATA18 in the asthenospermia group can represent this gene's critical function in sperm motility and fertility. The present study aimed to assess the relationship between SPATA18 and P53 gene expression in sperm cells obtained from normospermia and asthenospermia.

Materials and Methods

In this case-control study, the quantitative real-time polymerase chain reaction (RT-PCR) technique was used to measure the SPATA18 and P53 gene expression level in sperm samples collected from 21 patients and 63 healthy individuals. Further, the sperm DNA fragmentation assay (SDFA) kit was applied to determine the relative apoptosis level in cells and evaluate the biochemical information related to the patients' sperm samples. Furthermore, all the participants completed the consent form, and the ethics committee confirmed the study.

Results

Based on the results, the P53 and SPATA18 gene expression levels in most of the samples, in which motility was less than 40%, increased and decreased (P≤0.001), respectively.

Conclusion

The SPATA18 and P53 gene expression levels increased and decreased in the asthenospermic patients, respectively, compared to the control group. Thus, the P53 and SPATA18 expression levels can be used as an appropriate marker for diagnosing sperm motility in males.

Down Regulation of Chemerin and Resistin in Type II Diabetic Rats Treated With Silver Nanoparticles Synthetized Using Eryngium thyrsoideum Boiss Extract

Introduction: Diabetes is related to the higher production of inflammatory markers such as chemerin and resistin. Hypoglycemic influences of Eryngium thyrsoideum Boiss and silver nanoparticles (SNPs) have been established. The present study investigated the impacts of chemically or biologically synthesized SNPs using E. thyrsoideum extract on chemerin and resistin gene expressions in type II diabetic rats. Methods: Twenty male Wistar rats weighing 180-200 g were used. Type 2 diabetes was induced by nicotinamide and streptozotocin. Saline and 2.5 mg/kg chemically or biologically synthesized SNPs were injected to diabetic rats for two weeks. Five healthy rats received saline for two weeks. One day after the last injection, fasting blood samples were collected. Mean serum concentrations of glucose, creatinine, urea, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured by spectrophotometry. The gene expression of chemerin and resistin was determined by real-time polymerase chain reaction (PCR). Results: Mean serum concentrations of glucose, urea, ALT, AST, and mean relative gene expression of chemerin and resistin remarkably decreased in the diabetic group receiving SNPs prepared by either the chemical method or using Eryngium extract compared to the diabetic control group. Serum creatinine concentration did not change significantly in the control diabetic or diabetic groups receiving SNPs prepared either chemically or using the Eryngium extract. Conclusion: Chemically or green synthesized SNPs prevent liver hepatocyte damage. They reduced inflammatory factors via exerting hypoglycemic effects.

Comparison of Thessaly Test with Joint Line Tenderness and McMurray Test in the Diagnosis of Meniscal Tears

Introduction:

Meniscus injuries are the most frequent problem of the knee. The aim of this study was to investigate the accuracy of the Thessaly test and comparing it with those of McMurray and Joint-line tenderness tests for diagnosing meniscal tears.

Materials and methods: This study was designed as a prospective observational one done in an outpatient clinic at a university hospital. 106 patients with knee pain and 82 age-matched control were included during study period (from February 2014 to January 2015). Each patient was clinically examined with McMurray, Thessaly, and joint line tenderness tests. Then, the findings were matched by MRI and arthroscopic findings. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy were calculated as main outcomes.

Results:

Based on MRI, Thessaly was the most sensitive for medial meniscus tears (56.2%), while McMurray and joint-line tenderness were more specific (89.1% and 88.0%, respectively). For lateral meniscus tears, McMurray was the most sensitive (56.2%) and all were specific (McMurray 89.6%, Thessaly 88.4%, joint-line tenderness 90.2%). With arthroscopy, Thessaly was the most sensitive for medial meniscus (76.6%), while McMurray and joint-line tenderness were more specific (81.0%, and 81.0%). Agreement with arthroscopy was the highest with McMurray (for medial meniscus kappa=0.40, p<0.001, and for lateral meniscus kappa=0.38, p=0.002).

Conclusion:

The Thessaly can be used to screen for medial meniscus tears. McMurray and joint-line tenderness should be used for suspected medial meniscus tears. For lateral meniscus, McMurray is appropriate for screening and all the tests are useful in clinic.

Effect of N-Acetylcysteine on Inflammatory and Biochemical Markers of Hemodialysis Patients: A Randomized Controlled Trial

Abstract- The oxidative stress results in atherosclerosis and cardiovascular diseases in patients receiving hemodialysis. N-acetylcysteine is a well-known antioxidant agent. There are little studies about the effect of N-acetylcysteine on patients receiving hemodialysis, and, if any, their results are inconsistent. This study, as a double-blind, randomized clinical trial, was conducted on 44 hemodialysis patients in Shahid Beheshti Hospital, Yasuj, Iran in 2015. Patients were randomly allocated into two groups, in the intervention group, N-acetylcysteine 600 mg every 12 hours for eight weeks was administered and the second group received placebo during this period every 12 hours. Blood samples were taken to measure C-reactive protein, interleukin-6 and other biochemical markers such as ferritin, albumin, and creatinine at baseline and at the end of treatment. 40 patients completed the study (21 on N-acetylcysteine, 19 on placebo), with a mean age of 60.72±17.60. There was not any significant difference between intervention and control groups in interleukin-6 (8.85±6.9 vs. 10.32±8.68, 95% CI, -3.52 to 6.46; P=0.55) and C - reactive protein (0.85±0.29 vs. 0.9±0.31, 95% CI, -.14 to .24; P=0.60). In addition, there was no significant relationship between the two groups in other biochemical markers. In this study, administering N-acetylcysteine was safe and caused a reduction in some inflammatory markers, but these changes were not significant in comparison with placebo.